http://www.reportbuyer.com/rss.htmlDiscover insightful information on Pharma Sales & Marketing. Reports include data on Drug Branding, Post Launch Marketing and Pharmaceutical Customer Relationship Management.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/pharmacies_drug_retailers_china.htmlThe IBISWorld Pharmacies and Drug Retailers in China industry report consists of establishment mainly engaged in the retailing of drugs, both western medicine and traditional Chinese medicine (TCM), products for birth control and sexual healthcare, and some other personal products. . a14d43187d2abe819c87394b30278028Wed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/leading_pharmaceutical_companies_marketing_tactics.htmlFor each company, the analysis presents: Sales force in the U. S. , Europe, Asia, and other geographic regions. e359dac3a1f2c130887fd5b8a03b8275Tue, 01 Sep 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/new_multi_marketing_channel_strategies.html The future of Pharma marketing lies in using new marketing channels such as social media intertwined with traditional marketing practices to create a multi-channel marketing mix. However, online brand promotion through social media is more effective for targeting patients than physicians, indicating direct marketing tactics to physicians through social media should be limited. Provides an overview of the reasons behind the need for new marketing channels Explores the different channel mixes used to reach the pharma industry's diverse customer base, both patients and doctors Examines the use of online social media technology and uses in-depth case study analysis to examine the pros and cons of each marketing channel Evaluates the future of online technology and how it can be used by Pharma marketing teams Social media is an excellent communication medium for pharma companies wishing to interact with patients, incorporating both disease and product information. ba936146bbff8d0435e42061db52d913Sat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/launching_next_generation_oncology_products.htmlThe emergence of a new wave of oncology products has been one of the most dramatic trends in the pharmaceutical market over the last decade. Both large and small companies are making unprecedented investments in oncology R&D, in an effort to emulate the success of new targeted therapies such as Herceptin, Avastin, Glivec, Nexavar and Erbitux. Underpinning that success have been real improvements in therapeutic options for a range of cancers, including marked survival increments in areas of poor prognosis, such as kidney cancer (e. 80070d7457cbbe45424cc531c31cfb1fSat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/pharmaceutical_sales_force_effectiveness_strategies.htmlThe social, demographic and economic context in which the pharmaceutical industry operates is changing dramatically, with huge implications for the industry as a whole. All these challenges have major ramifications for the way in which pharmaceutical companies market and sell the medicines they develop. With these challenges comes pressure to gain efficiencies in all facets of the business, but perhaps no aspect of pharma operations is under as much scrutiny as the sales and marketing function. e4ab7a14c6efa45337a0ec6a30e3d508Sat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/eastern_european_pharmaceutical_market_outlook_2014.htmlAlthough pharma companies have traditionally enjoyed considerable success in Eastern European markets, healthcare systems in the region have become increasingly complex in recent years. Governments have begun launching healthcare reforms to reduce costs, and new legislation has started to shift decision-making responsibility for prescription drugs from physicians to pharmacies. Many new member states have replaced state-controlled healthcare systems with regulated social health insurance systems and several countries have also opened up their health insurance markets to competition from private insurers. 2ecb7983e08b5bd19ec0a6068488d95aSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/research_report_third_terminal_market_chinese_medinces_2009.htmlThe medicine terminals refer to the places where the consumers face the medicines directly, realize the exchange between currencies and medicines and the last step for the medicines to circulate from the manufacturers to the consumers. Among the various circulation steps, the medicine terminals are the place for the manufacturers to realize the medicine sales. The definition of the third terminal market is different from the first terminal market and the second terminal market. 9bf10592b889dd6a8eff11ebf49e578dTue, 05 May 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/reinventing_pharmaceutical_sales_forces.htmlInnovate your sales practices to reach and influence targets More Pharmaceutical Sales Information: National Association of Pharmaceutical Sales Representatives The "more is better" methodology of selling is dead. The Wall Street Journal now predicts that the number of pharmaceutical sales reps in the US will drop to 70,000 by the year 2015. This is a tremendous change from the boom of the 1990s and early 2000s, when the total number of reps exceeded 100,000. 3831b876b0668298df1eb693a2074f32Tue, 05 May 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/optimizing_key_opintion_leader_relationships.htmlStudy Overview The advocacy of Key Opinion Leaders (KOLs) has proven to be among the most effective and critical means of building product awareness in the medical and scientific communities. Indeed, KOL relationship management itself has emerged as its own business discipline, a necessary and challenging component of brand promotion. as one interviewed director put it, "KOL relationship management has changed very quickly. 2c6ce6e141817c44c7d6eb5af707ba4bSat, 04 Apr 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/using_public_relations_launch_grow_extend_brands.htmlSavvier consumers and competition from generic drugs have made commercial success, whether at market entry or during brand maturity, more elusive. at the same time, new technologies have greatly expanded the ability of cost-efficient Public Relations to support pharmaceutical brand growth. Thus, while industry trends introduce challenges to product commercialization, technology is enabling PR leaders to fashion innovative PR campaigns. def2f949bc5ae93db21faa7cb8b94263Tue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/stakeholder_opinions_tuberculosis_development_pipeline_shows_signs_life.html Tuberculosis is a major cause of illness and death worldwide, but despite 14. 4 million prevalent cases, 9. 2 million new cases and 1. 7c6f084b2e6f839202c22ffb6de2befbTue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/forecast_insight_opioids_saturation_limits_commercial_potential_individual_brands.html The opioids market is set to grow from $9. 6 billion in 2008 to $11. 9 billion in 2018 across the seven major markets. 2ec445a53277545158bdbaa6c5994f6bTue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/pipeline_commercial_insight_nicotine_dependence_chantix_issues_overshadow_vaccine_potential.html With a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence market represents a lucrative opportunity for pharmaceutical companies. With strong uptake since launch in 2006 of Pfizer's Chantix (varenicline), the seven major prescription nicotine dependence market was estimated to total $1. 35 billion in 2008. b3624821c26b8d32b596221c6dbf1caeTue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/stakeholder_opinions_back_pain_gain_competitive_edge_targeting_subpopulations.html Back pain can restrict activity and quality of everyday life and in some cases is a potentially chronic and even crippling condition. Therefore, back pain exerts a large economic impact on society. Due to the high prevalence of back pain, Datamonitor believes that the condition represents a commercially attractive target to pharmaceutical companies with an interest in the pain market. dc10d2e269cbb0eb7b2b3f97d678cce9Tue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/stakeholder_opinions_pulmonary_arterial_hypertension_clinical_community_builds_order_chaos.html Despite an explosion in the number of drugs and treatment strategies available, pulmonary arterial hypertension is still a rapidly fatal condition for a small, hard to identify patient group. A small clinical elite is currently leading the way in advancing treatment outcomes, and is central to determining which new treatment strategies are used. Defining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challenge Translation of critical clinical issues into pertinent practical considerations for both incumbent players and new market entrants Insight into the challenge of determining a patient potential in the context of a miniscule diagnosed population and a phenomenal "at-risk" population Assessment of future directions in management and the changing roles of therapies The estimated 8,11516,186 diagnosed pulmonary arterial hypertension patients across the US, Japan, France, Germany, Italy, Spain and the UK represent a fraction of the 28. e5fbc4e3847f07d6dd6b657d9f25bd75Tue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/european_cme_forum_first_annual_meeting.htmlThe European landscape for continuing medical education (CME) is diverse and complex. The absence of a common framework across the region has led to individual countries developing their own national objectives and building a range of systems, each at differing stages of advancement. While similarities in approach exist, the key European markets demonstrate notable differences in both style and in how CME is being implemented. c4708d39fb5f9220a0e50bee7196fe80Mon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/medical_science_liaisons.htmlStudy Overview as companies compete for the attention of physicians, key opinion leaders (KOLs) and thought leaders, they increasingly use medical science liaisons (MSLs) to build and strengthen KOL relationships. as laws continue to restrict relationships between pharmaceutical companies and physicians, finding the right way to build and maintain relationships can have a dramatic impact on company success. This research uncovers the optimal size, mix and service frequencies of these elite medical specialist groups in an effort to build strong, productive relationships. f3b7ba0b3a78b3b2fb801f6684fbc38aMon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/key_opinion_leaders_1.htmlIncrease thought leader participation and solidify opinion leader efforts: Plagued by low thought leader participation? Do your thought leader recruitment efforts feel scattershot or unproductive? Do you want to ensure that your documentation processes are fail-proof? If you answered "yes" to any of the above, Key Opinion Leaders: Relationship Management and Segmentation Data is essential. This is a definitive guide for engaging thought leaders in today's increasingly transparent environment. It shows teams how to be proactive and forward-thinking even while feeling the weight of ongoing regulatory pressure. bd59bfb3de5b3f890ee989ebb95b9ba8Mon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/antithrombotics_market_forecast.htmlIntroductionThe antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and warfarin, respectively). Reasons to PurchaseQuantify the future size and understand the background of the antithrombotics marketUnderstand the commercial landscape in terms of new product potentialUnderstand the barriers to uptake for novel antithrombotics. 3448d625fdc78e26fbf274aacef6ab23Thu, 01 Jan 2009 12:00:00 GBPharma & Healthcare/Sales & Marketinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/cv_diabetes_market_forecast.htmlIntroductionDatamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0. 9% in the seven major markets. 4899f6eabfe9430844e1b1f25a9ac48eThu, 01 Jan 2009 12:00:00 GBPharma & Healthcare/Sales & Marketing